1
|
Veltman CHJ, Pennings JLA, van de Water B, Luijten M. An Adverse Outcome Pathway Network for Chemically Induced Oxidative Stress Leading to (Non)genotoxic Carcinogenesis. Chem Res Toxicol 2023. [PMID: 37156502 DOI: 10.1021/acs.chemrestox.2c00396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Nongenotoxic (NGTX) carcinogens induce cancer via other mechanisms than direct DNA damage. A recognized mode of action for NGTX carcinogens is induction of oxidative stress, a state in which the amount of oxidants in a cell exceeds its antioxidant capacity, leading to regenerative proliferation. Currently, carcinogenicity assessment of environmental chemicals primarily relies on genetic toxicity end points. Since NGTX carcinogens lack genotoxic potential, these chemicals may remain undetected in such evaluations. To enhance the predictivity of test strategies for carcinogenicity assessment, a shift toward mechanism-based approaches is required. Here, we present an adverse outcome pathway (AOP) network for chemically induced oxidative stress leading to (NGTX) carcinogenesis. To develop this AOP network, we first investigated the role of oxidative stress in the various cancer hallmarks. Next, possible mechanisms for chemical induction of oxidative stress and the biological effects of oxidative damage to macromolecules were considered. This resulted in an AOP network, of which associated uncertainties were explored. Ultimately, development of AOP networks relevant for carcinogenesis in humans will aid the transition to a mechanism-based, human relevant carcinogenicity assessment that involves a substantially lower number of laboratory animals.
Collapse
Affiliation(s)
- Christina H J Veltman
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands
| | - Jeroen L A Pennings
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands
| | - Bob van de Water
- Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2333 CC Leiden, The Netherlands
| | - Mirjam Luijten
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands
| |
Collapse
|
2
|
Dos Santos Rodrigues B, Leroy K, Mihajlovic M, De Boever S, Vanbellingen S, Cogliati B, Aerts JL, Vinken M. Evaluation of functional candidate biomarkers of non-genotoxic hepatocarcinogenicity in human liver spheroid co-cultures. Arch Toxicol 2023; 97:1739-1751. [PMID: 36941454 DOI: 10.1007/s00204-023-03486-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 03/13/2023] [Indexed: 03/22/2023]
Abstract
Validated in vitro assays for testing non-genotoxic carcinogenic potential of chemicals are currently not available. Consequently, the two-year rodent bioassay remains the gold standard method for the identification of these chemicals. Transcriptomic and proteomic analyses have provided a comprehensive understanding of the non-genotoxic carcinogenic processes, however, functional changes induced by effects at transcriptional and translational levels have not been addressed. The present study was set up to test a number of proposed in vitro biomarkers of non-genotoxic hepatocarcinogenicity at the functional level using a translational 3-dimensional model. Spheroid cultures of human hepatocytes and stellate cells were exposed to 5 genotoxic carcinogenic, 5 non-genotoxic carcinogenic, and 5 non-carcinogenic chemical compounds and assessed for oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, apoptosis, and inflammation. The spheroid model could capture many of these events triggered by the genotoxic carcinogenic chemicals, particularly aflatoxin B1 and hydroquinone. Nonetheless, no clear distinction could be made between genotoxic and non-genotoxic hepatocarcinogenicity. Therefore, spheroid cultures of human liver cells may be appropriate in vitro tools for mechanistic investigation of chemical-induced hepatocarcinogenicity, however, these mechanisms and their read-outs do not seem to be eligible biomarkers for detecting non-genotoxic carcinogenic chemicals.
Collapse
Affiliation(s)
- Bruna Dos Santos Rodrigues
- Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium
| | - Kaat Leroy
- Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium
| | - Milos Mihajlovic
- Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium
| | - Sybren De Boever
- Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium
| | - Sarah Vanbellingen
- Entity of Neuro-Aging and Viro-Immunotherapy, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussels, Belgium
| | - Bruno Cogliati
- School of Veterinary Medicine and Animal Science, Department of Pathology, University of São Paulo, São Paulo, Brazil
| | - Joeri L Aerts
- Entity of Neuro-Aging and Viro-Immunotherapy, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussels, Belgium
| | - Mathieu Vinken
- Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.
| |
Collapse
|
3
|
Herlin M, Sánchez-Pérez I, Esteban J, Korkalainen M, Barber X, Finnilä MAJ, Hamscher G, Joseph B, Viluksela M, Håkansson H. Bone toxicity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the retinoid system: A causality analysis anchored in osteoblast gene expression and mouse data. Reprod Toxicol 2021; 105:25-43. [PMID: 34363983 DOI: 10.1016/j.reprotox.2021.07.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Revised: 07/16/2021] [Accepted: 07/30/2021] [Indexed: 12/18/2022]
Abstract
Dioxin exposures impact on bone quality and osteoblast differentiation, as well as retinoic acid metabolism and signaling. In this study we analyzed associations between increased circulating retinol concentrations and altered bone mineral density in a mouse model following oral exposure to 2,3,7,8-tetrachlordibenzo-p-dioxin (TCDD). Additionally, effects of TCDD on differentiation marker genes and genes involved with retinoic acid metabolism were analysed in an osteoblast cell model followed by benchmark dose-response analyses of the gene expression data. Study results show that the increased trabecular and decreased cortical bone mineral density in the mouse model following TCDD exposure are associated with increased circulating retinol concentrations. Also, TCDD disrupted the expression of genes involved in osteoblast differentiation and retinoic acid synthesis, degradation, and nuclear translocation in directions compatible with increasing cellular retinoic acid levels. Further evaluation of the obtained results in relation to previously published data by the use of mode-of-action and weight-of-evidence inspired analytical approaches strengthened the evidence that TCDD-induced bone and retinoid system changes are causally related and compatible with an endocrine disruption mode of action.
Collapse
Affiliation(s)
- Maria Herlin
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
| | - Ismael Sánchez-Pérez
- Instituto de Bioingeniería, Universidad Miguel Hernández de Elche, Elche, Alicante, Spain.
| | - Javier Esteban
- Instituto de Bioingeniería, Universidad Miguel Hernández de Elche, Elche, Alicante, Spain.
| | - Merja Korkalainen
- Environmental Health Unit, Finnish Institute for Health and Welfare (THL), Kuopio, Finland.
| | - Xavier Barber
- Centro de Investigación Operativa, Universidad Miguel Hernández, Elche, Alicante, Spain.
| | - Mikko A J Finnilä
- Research Unit of Medical Imaging, Physics, and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland.
| | - Gerd Hamscher
- Institute of Food Chemistry and Food Biotechnology, Justus Liebig University Giessen, 10 Giessen, Germany.
| | - Bertrand Joseph
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
| | - Matti Viluksela
- Environmental Health Unit, Finnish Institute for Health and Welfare (THL), Kuopio, Finland; School of Pharmacy (Toxicology) and Department of Environmental and Biological Sciences, University of Eastern Finland, Kuopio, Finland.
| | - Helen Håkansson
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
4
|
Clergé A, Le Goff J, Lopez-Piffet C, Meier S, Lagadu S, Vaudorne I, Babin V, Cailly T, Delépée R. Investigation by mass spectrometry and 32P post-labelling of DNA adducts formation from 1,2-naphthoquinone, an oxydated metabolite of naphthalene. CHEMOSPHERE 2021; 263:128079. [PMID: 33297078 DOI: 10.1016/j.chemosphere.2020.128079] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 07/08/2020] [Accepted: 08/19/2020] [Indexed: 06/12/2023]
Abstract
Naphthalene is the simplest representative of polycyclic aromatic hydrocarbons (PAHs). It is detected as major pollutant in the different compartments of the environment. This compound is considered by the international agency for research on cancer (IARC), the specialized cancer agency of the World Health Organisation (WHO), as a possible carcinogenic (group 2B) since 2002, mainly based on studies on chronic inhalation in rodent by the national toxicology program of the U.S. department of health and human services. In humans, its main metabolites correspond to derivatives substituted in position and 1 and 2 as 1,2-naphthoquinone (1,2-NphQ). Based on previous studies, 1,2-NphQ is supposed to react with DNA to form mostly depurinating adducts, a possible initiating step of carcinogenicity. To confirm this potentiality, adducts were synthetized by the reaction of 1,2-NphQ with 2'-deoxyguanosine (2'-dG) in N,N-dimethylformamide (DMF), water and calf thymus DNA. 2'-dG adducts were analyzed by 32P post-labelling, HPLC with ultra-violet detection and ultra-performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS). We found stable DNA adducts detected in DNA. We proposed a formation mechanism by a 1,4-Michael addition with 2'-dG. Adducts with 2'-deoxyxanthosine are formed after a spontaneous deamination of 2'-dG. These adducts are good candidates as biomarkers allowing evaluation of exposure to naphthalene and its derivatives in the development of pathologies such as cancer.
Collapse
Affiliation(s)
- Adeline Clergé
- Normandy University, UNICAEN, UNIROUEN, ABTE, Caen, France.
| | | | - Claire Lopez-Piffet
- Normandy University, UNICAEN, UNIROUEN, ABTE, Caen, France; Normandy University, UNICAEN, PRISMM Platform ICORE, Caen, France
| | | | - Stéphanie Lagadu
- Normandy University, UNICAEN, UNIROUEN, ABTE, Caen, France; Normandy University, UNICAEN, PRISMM Platform ICORE, Caen, France; Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - Isabelle Vaudorne
- Normandy University, UNICAEN, UNIROUEN, ABTE, Caen, France; Normandy University, UNICAEN, PRISMM Platform ICORE, Caen, France; Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - Victor Babin
- Normandy University, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), 14000, Caen, France
| | - Thomas Cailly
- Normandy University, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), 14000, Caen, France; Normandy University, UNICAEN, IMOGERE, Caen, France; Department of Nuclear Medicine, CHU Côte de Nacre, Caen, France
| | - Raphaël Delépée
- Normandy University, UNICAEN, UNIROUEN, ABTE, Caen, France; Normandy University, UNICAEN, PRISMM Platform ICORE, Caen, France; Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France.
| |
Collapse
|
5
|
Heusinkveld H, Braakhuis H, Gommans R, Botham P, Corvaro M, van der Laan JW, Lewis D, Madia F, Manou I, Schorsch F, Wolterink G, Woutersen R, Corvi R, Mehta J, Luijten M. Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals. Crit Rev Toxicol 2020; 50:725-739. [DOI: 10.1080/10408444.2020.1841732] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Harm Heusinkveld
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Hedwig Braakhuis
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Robin Gommans
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | | | | | | | | | - Federica Madia
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Irene Manou
- European Partnership for Alternative Approaches to Animal Testing (EPAA), Brussels, Belgium
| | | | - Gerrit Wolterink
- Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Ruud Woutersen
- TNO Quality of Life, Zeist, and Wageningen University & Research, Wageningen, the Netherlands
| | - Raffaella Corvi
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | | | - Mirjam Luijten
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| |
Collapse
|
6
|
Brescia S. Thresholds of adversity and their applicability to endocrine disrupting chemicals. Crit Rev Toxicol 2020; 50:213-218. [PMID: 32228218 DOI: 10.1080/10408444.2020.1740973] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Within the European Union, various legislative acts contain specific provisions on endocrine disruption, requiring the regulation of substances with endocrine disrupting properties via a hazard-based approach. Presumably this is due to an assumed lack of thresholds for the adverse effects of such substances. Conversely, in other jurisdictions, such as USA, Canada, Australia and Japan, endocrine disruptors (EDs) are regulated using a risk-based approach. As a consequence, in recent years there has been increasing controversy on whether thresholds can be inferred for endocrine-mediated effects. There is concern that the endocrine system is too complex to allow estimation of safe levels of exposure to such chemicals. This brief review aims to evaluate the available scientific evidence in this area and offer a sound and robust conclusion supported by this analysis. It is concluded that there is nothing special or unique about endocrine disruption or greater uncertainties in its assessment compared to other non-genotoxic forms of toxicity to justify adopting a non-threshold approach by default. Biology predicts that thresholds of adversity exist and are the rule for all endpoints, including those arising from endocrine disruption. A threshold approach to the risk assessment of endocrine disrupting chemicals is scientifically justified.
Collapse
Affiliation(s)
- Susy Brescia
- Health and Safety Executive (HSE), Chemicals Regulation Division (CRD), Merseyside, UK
| |
Collapse
|
7
|
Felter SP, Boobis AR, Botham PA, Brousse A, Greim H, Hollnagel HM, Sauer UG. Hazard identification, classification, and risk assessment of carcinogens: too much or too little? - Report of an ECETOC workshop. Crit Rev Toxicol 2020; 50:72-95. [PMID: 32133908 DOI: 10.1080/10408444.2020.1727843] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) organized a workshop "Hazard Identification, Classification and Risk Assessment of Carcinogens: Too Much or Too Little?" to explore the scientific limitations of the current binary carcinogenicity classification scheme that classifies substances as either carcinogenic or not. Classification is often based upon the rodent 2-year bioassay, which has scientific limitations and is not necessary to predict whether substances are likely human carcinogens. By contrast, tiered testing strategies founded on new approach methodologies (NAMs) followed by subchronic toxicity testing, as necessary, are useful to determine if a substance is likely carcinogenic, by which mode-of-action effects would occur and, for non-genotoxic carcinogens, the dose levels below which the key events leading to carcinogenicity are not affected. Importantly, the objective is not for NAMs to mimic high-dose effects recorded in vivo, as these are not relevant to human risk assessment. Carcinogenicity testing at the "maximum tolerated dose" does not reflect human exposure conditions, but causes major disturbances of homeostasis, which are very unlikely to occur at relevant human exposure levels. The evaluation of findings should consider biological relevance and not just statistical significance. Using this approach, safe exposures to non-genotoxic substances can be established.
Collapse
Affiliation(s)
| | | | | | - Alice Brousse
- European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), Brussels, Belgium
| | | | | | - Ursula G Sauer
- Scientific Consultancy - Animal Welfare, Neubiberg, Germany
| |
Collapse
|
8
|
Clergé A, Le Goff J, Lopez C, Ledauphin J, Delépée R. Oxy-PAHs: occurrence in the environment and potential genotoxic/mutagenic risk assessment for human health. Crit Rev Toxicol 2019; 49:302-328. [DOI: 10.1080/10408444.2019.1605333] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Adeline Clergé
- Normandie Univ, UNICAEN, UNIROUEN, ABTE, Caen Cedex, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen Cedex, France
| | | | - Claire Lopez
- Normandie Univ, UNICAEN, UNIROUEN, ABTE, Caen Cedex, France
| | | | - Raphaël Delépée
- Normandie Univ, UNICAEN, UNIROUEN, ABTE, Caen Cedex, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen Cedex, France
- Normandie Univ, UNICAEN, PRISMM core facility, SF4206 ICORE, CCC F. Baclesse, Caen, France
| |
Collapse
|
9
|
Perkins EJ, Ashauer R, Burgoon L, Conolly R, Landesmann B, Mackay C, Murphy CA, Pollesch N, Wheeler JR, Zupanic A, Scholz S. Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment. ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY 2019; 38:1850-1865. [PMID: 31127958 PMCID: PMC6771761 DOI: 10.1002/etc.4505] [Citation(s) in RCA: 84] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 03/26/2019] [Accepted: 05/21/2019] [Indexed: 05/20/2023]
Abstract
An important goal in toxicology is the development of new ways to increase the speed, accuracy, and applicability of chemical hazard and risk assessment approaches. A promising route is the integration of in vitro assays with biological pathway information. We examined how the adverse outcome pathway (AOP) framework can be used to develop pathway-based quantitative models useful for regulatory chemical safety assessment. By using AOPs as initial conceptual models and the AOP knowledge base as a source of data on key event relationships, different methods can be applied to develop computational quantitative AOP models (qAOPs) relevant for decision making. A qAOP model may not necessarily have the same structure as the AOP it is based on. Useful AOP modeling methods range from statistical, Bayesian networks, regression, and ordinary differential equations to individual-based models and should be chosen according to the questions being asked and the data available. We discuss the need for toxicokinetic models to provide linkages between exposure and qAOPs, to extrapolate from in vitro to in vivo, and to extrapolate across species. Finally, we identify best practices for modeling and model building and the necessity for transparent and comprehensive documentation to gain confidence in the use of qAOP models and ultimately their use in regulatory applications. Environ Toxicol Chem 2019;38:1850-1865. © 2019 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals, Inc. on behalf of SETAC.
Collapse
Affiliation(s)
- Edward J. Perkins
- US Army Engineer Research and Development CenterVicksburgMississippiUSA
| | - Roman Ashauer
- Environment DepartmentUniversity of York, HeslingtonYorkUK
- ToxicodynamicsYorkUK
| | - Lyle Burgoon
- US Army Engineer Research and Development CenterVicksburgMississippiUSA
| | - Rory Conolly
- Integrated Systems Toxicology Division, National Health and Environmental Effects Research Laboratory, Office of Research and DevelopmentUS Environmental Protection Agency, Research Triangle ParkNorth CarolinaUSA
| | | | - Cameron Mackay
- Unilever Safety and Environmental Assurance Centre, SharnbrookBedfordUK
| | - Cheryl A. Murphy
- Department of Fisheries and WildlifeMichigan State UniversityEast LansingMichiganUSA
| | - Nathan Pollesch
- Mid‐Continent Ecology Division, National Health and Environmental Effects Laboratory, Office of Research and DevelopmentUS Environmental Protection AgencyDuluthMinnesotaUSA
| | | | - Anze Zupanic
- Department of Environmental ToxicologySwiss Federal Institute for Aquatic Science and TechnologyDübendorfSwitzerland
| | - Stefan Scholz
- Department of Bioanalytical EcotoxicologyHelmholtz Centre for Environmental Research‐UFZLeipzigGermany
| |
Collapse
|
10
|
Mechanistic integration of exposure and effects: advances to apply systems toxicology in support of regulatory decision-making. CURRENT OPINION IN TOXICOLOGY 2019. [DOI: 10.1016/j.cotox.2019.09.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
11
|
Schmitz-Spanke S. Toxicogenomics - What added Value Do These Approaches Provide for Carcinogen Risk Assessment? ENVIRONMENTAL RESEARCH 2019; 173:157-164. [PMID: 30909101 DOI: 10.1016/j.envres.2019.03.025] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 03/08/2019] [Accepted: 03/10/2019] [Indexed: 06/09/2023]
Abstract
It is still a major challenge to protect humans at workplaces and in the environment. To cope with this task, it is a prerequisite to obtain detailed information on the extent of chemical perturbations of biological pathways, in particular, adaptive vs. adverse effects and the dose-response relationships. This knowledge serves as the basis for the classification of non-carcinogens and carcinogens and for further distinguishing carcinogens in genotoxic (DNA damaging) or non-genotoxic compounds. Basing on quantitative dose-response relationships, points of departures can be derived for chemical risk assessment. In recent years, new methods have shown their capability to support the established rodent models of carcinogenicity testing. In vitro high throughput screening assays assess more comprehensively cell response. In addition, omics technologies were applied to study the mode of action of chemicals whereby the term "toxicogenomics" comprises various technologies such as transcriptomics, epigenomics, or metabolomics. This review aims to summarize the current state of toxicogenomic approaches in risk science and to compare them with established ones. For example, measurement of global transcriptional changes generates meaningful information for toxicological risk assessment such as accurate classification of genotoxic/non-genotoxic carcinogens. Alteration in mRNA expression offers previously unknown insights in the mode of action and enables the definition of key events. Based on these, benchmark doses can be calculated for the transition from an adaptive to an adverse state. In short, this review assesses the potential and challenges of transcriptomics and addresses the impact of other omics technologies on risk assessment in terms of hazard identification and dose-response assessment.
Collapse
Affiliation(s)
- Simone Schmitz-Spanke
- Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, University of Erlangen-Nuremberg, Henkestr. 9-11, 91054, Erlangen, Germany.
| |
Collapse
|
12
|
Endocrine Disruption: Current approaches for regulatory testing and assessment of plant protection products are fit for purpose. Toxicol Lett 2018; 296:10-22. [PMID: 30006252 DOI: 10.1016/j.toxlet.2018.07.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 07/06/2018] [Accepted: 07/09/2018] [Indexed: 11/23/2022]
Abstract
The ongoing debate concerning the regulation of endocrine disruptors, has increasingly led to questions concerning the current testing of chemicals and whether this is adequate for the assessment of potential endocrine disrupting effects. This paper describes the current testing approaches for plant protection product (PPP) active substances in the European Union and the United States and how they relate to the assessment of endocrine disrupting properties for human and environmental health. This includes a discussion of whether the current testing approaches cover modalities other than the estrogen, androgen, thyroid and steroidogenesis (EATS) pathways, sensitive windows of exposure, adequate assessment of human endocrine disorders and wildlife species, and the determination of thresholds for endocrine disruption. It is concluded, that the scope and nature of the core and triggered data requirements for PPP active substances are scientifically robust to address adverse effects mediated through endocrine mode(s) of action and to characterise these effects in terms of dose response.
Collapse
|
13
|
Thompson CM, Suh M, Proctor DM, Chappell G, Borghoff S, Ellis-Hutchings R, Wiench K, Finch L. Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans. Regul Toxicol Pharmacol 2018; 96:178-189. [PMID: 29738809 DOI: 10.1016/j.yrtph.2018.05.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 04/22/2018] [Accepted: 05/02/2018] [Indexed: 02/07/2023]
Abstract
Chronic repeated gavage dosing of high concentrations of ethyl acrylate (EA) causes forestomach tumors in rats and mice. For two decades, there has been general consensus that these tumors are unique to rodents because of: i) lack of carcinogenicity in other organs, ii) specificity to the forestomach (an organ unique to rodents which humans do not possess), iii) lack of carcinogenicity by other routes of exposure, and iv) obvious site of contact toxicity at carcinogenic doses. In 1986, EA was classified as possibly carcinogenic to humans by the International Agency for Research on Cancer (IARC). However, by applying a MOA analyses and human relevance framework assessment, the weight-of-evidence supports a cytotoxic MOA with the following key events: i) bolus delivery of EA to forestomach lumen and subsequent absorption, ii) cytotoxicity likely due to saturation of enzymatic detoxification, iii) chronic regenerative hyperplasia, and iv) spontaneous mutation due to increased cell replication and cell population. Clonal expansion of initiated cells thus results in late onset tumorigenesis. The key events in this 'wound and healing' MOA provide high confidence in the MOA as assessed by evolved Bradford-Hill Criteria. The weight-of-evidence supported by the proposed MOA, combined with a unique tissue that does not exist in humans, indicates that EA is highly unlikely to pose a human cancer hazard.
Collapse
Affiliation(s)
| | - Mina Suh
- ToxStrategies, Inc., Mission Viejo, CA 92692, United States
| | | | | | | | | | | | | |
Collapse
|
14
|
Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. An Adverse Outcome Pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol 2018; 96:30-40. [PMID: 29684431 DOI: 10.1016/j.yrtph.2018.04.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2018] [Revised: 04/15/2018] [Accepted: 04/18/2018] [Indexed: 02/07/2023]
Abstract
The utility of rodent forestomach tumor data for hazard and risk assessment has been examined for decades because humans do not have a forestomach, and these tumors occur by varying modes of action (MOAs). We have used the MOA for ethyl acrylate (EA) to develop an Adverse Outcome Pathway (AOP) for forestomach tumors caused by non-genotoxic initiating events. These tumors occur secondary to site of contact induced epithelial cytotoxicity and regenerative repair-driven proliferation. For EA, the critical initiating event (IE) is epithelial cytotoxicity, and supporting key events (KEs) at the cellular and tissue level are increased cell proliferation (KE1) resulting in sustained hyperplasia (KE2), with the adverse outcome of forestomach papillomas and carcinomas. For EA, a pre-molecular initiating event (pre-MIE) of sustained glutathione depletion is probable. Supporting data from butylated hydroxyanisole (BHA) are also reviewed. Although there may be some variability in the pre-MIEs and IEs for BHA and EA, they share the same KEs, and evidence for BHA confers support for the AOP. Evolved Bradford Hill considerations of biological plausibility, essentiality, and empirical support were evaluated per OECD guidance. Although an MIE is not specifically described, overall confidence in the AOP is high due to well-developed and accepted evidence streams, and the AOP can be used for regulatory applications including hazard identification and risk assessment for chemicals that act by this AOP.
Collapse
Affiliation(s)
| | - Mina Suh
- ToxStrategies, Inc., Mission Viejo, CA 92692, USA
| | | | | | | | | | | | | |
Collapse
|
15
|
The role of ethyl acrylate induced GSH depletion in the rodent forestomach and its impact on MTD and in vivo genotoxicity in developing an adverse outcome pathway (AOP). Regul Toxicol Pharmacol 2018; 92:173-181. [DOI: 10.1016/j.yrtph.2017.11.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Revised: 11/15/2017] [Accepted: 11/19/2017] [Indexed: 02/04/2023]
|
16
|
The challenge of the application of 'omics technologies in chemicals risk assessment: Background and outlook. Regul Toxicol Pharmacol 2017; 91 Suppl 1:S14-S26. [DOI: 10.1016/j.yrtph.2017.09.020] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Revised: 09/12/2017] [Accepted: 09/13/2017] [Indexed: 11/21/2022]
|
17
|
Thompson CM, Suh M, Proctor DM, Haws LC, Harris MA. Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2017; 823:45-57. [DOI: 10.1016/j.mrgentox.2017.08.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 08/26/2017] [Accepted: 08/28/2017] [Indexed: 12/28/2022]
|
18
|
Framework for the quantitative weight-of-evidence analysis of 'omics data for regulatory purposes. Regul Toxicol Pharmacol 2017; 91 Suppl 1:S46-S60. [PMID: 29037774 DOI: 10.1016/j.yrtph.2017.10.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Revised: 10/11/2017] [Accepted: 10/12/2017] [Indexed: 01/01/2023]
Abstract
A framework for the quantitative weight-of-evidence (QWoE) analysis of 'omics data for regulatory purposes is presented. The QWoE framework encompasses seven steps to evaluate 'omics data (also together with non-'omics data): (1) Hypothesis formulation, identification and weighting of lines of evidence (LoEs). LoEs conjoin different (types of) studies that are used to critically test the hypothesis. As an essential component of the QWoE framework, step 1 includes the development of templates for scoring sheets that predefine scoring criteria with scores of 0-4 to enable a quantitative determination of study quality and data relevance; (2) literature searches and categorisation of studies into the pre-defined LoEs; (3) and (4) quantitative assessment of study quality and data relevance using the respective pre-defined scoring sheets for each study; (5) evaluation of LoE-specific strength of evidence based upon the study quality and study relevance scores of the studies conjoined in the respective LoE; (6) integration of the strength of evidence from the individual LoEs to determine the overall strength of evidence; (7) characterisation of uncertainties and conclusion on the QWoE. To put the QWoE framework in practice, case studies are recommended to confirm the relevance of its different steps, or to adapt them as necessary.
Collapse
|
19
|
Buesen R, Chorley BN, da Silva Lima B, Daston G, Deferme L, Ebbels T, Gant TW, Goetz A, Greally J, Gribaldo L, Hackermüller J, Hubesch B, Jennen D, Johnson K, Kanno J, Kauffmann HM, Laffont M, McMullen P, Meehan R, Pemberton M, Perdichizzi S, Piersma AH, Sauer UG, Schmidt K, Seitz H, Sumida K, Tollefsen KE, Tong W, Tralau T, van Ravenzwaay B, Weber RJM, Worth A, Yauk C, Poole A. Applying 'omics technologies in chemicals risk assessment: Report of an ECETOC workshop. Regul Toxicol Pharmacol 2017; 91 Suppl 1:S3-S13. [PMID: 28958911 DOI: 10.1016/j.yrtph.2017.09.002] [Citation(s) in RCA: 81] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 08/31/2017] [Accepted: 09/02/2017] [Indexed: 10/18/2022]
Abstract
Prevailing knowledge gaps in linking specific molecular changes to apical outcomes and methodological uncertainties in the generation, storage, processing, and interpretation of 'omics data limit the application of 'omics technologies in regulatory toxicology. Against this background, the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) convened a workshop Applying 'omics technologies in chemicals risk assessment that is reported herein. Ahead of the workshop, multi-expert teams drafted frameworks on best practices for (i) a Good-Laboratory Practice-like context for collecting, storing and curating 'omics data; (ii) the processing of 'omics data; and (iii) weight-of-evidence approaches for integrating 'omics data. The workshop participants confirmed the relevance of these Frameworks to facilitate the regulatory applicability and use of 'omics data, and the workshop discussions provided input for their further elaboration. Additionally, the key objective (iv) to establish approaches to connect 'omics perturbations to phenotypic alterations was addressed. Generally, it was considered promising to strive to link gene expression changes and pathway perturbations to the phenotype by mapping them to specific adverse outcome pathways. While further work is necessary before gene expression changes can be used to establish safe levels of substance exposure, the ECETOC workshop provided important incentives towards achieving this goal.
Collapse
Affiliation(s)
| | | | | | | | | | - Timothy Ebbels
- Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, United Kingdom
| | - Timothy W Gant
- Centre for Radiation, Chemical and Environmental Hazards (CRCE), Harwell Science and Innovation Campus, Public Health England (PHE), United Kingdom
| | | | - John Greally
- Albert Einstein College of Medicine, Yeshiva University, USA
| | - Laura Gribaldo
- European Commission, Joint Research Centre, European Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Italy
| | - Jörg Hackermüller
- Department of Molecular Systems Biology, Helmholtz Centre for Environmental Research - UFZ, Germany
| | | | - Danyel Jennen
- Department of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, The Netherlands
| | | | - Jun Kanno
- Japan Organization of Occupational Health and Safety, Japan
| | | | - Madeleine Laffont
- European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), Belgium
| | | | - Richard Meehan
- MRC Human Genetics Unit, IGMM, University of Edinburgh, Scotland, United Kingdom
| | | | - Stefania Perdichizzi
- Center for Environmental Toxicology, Agency for Prevention, Environment and Energy (Arpae), Emilia-Romagna, Italy
| | - Aldert H Piersma
- National Institute for Public Health and the Environment (RIVM), The Netherlands; IRAS Institute for Risk Assessment Sciences, Utrecht University, The Netherlands
| | | | | | - Hervé Seitz
- Institut de Génétique Humain (IGH), Centre National de la Recherche Scientifique - National Centre of Scientific Research (CNRS), France
| | | | | | - Weida Tong
- National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration (FDA), USA
| | - Tewes Tralau
- Department of Chemical and Product Safety, German Federal Institute of Risk Assessment (BfR), Germany
| | | | - Ralf J M Weber
- Phenome Centre Birmingham, School of Biosciences, University of Birmingham, United Kingdom
| | - Andrew Worth
- European Commission, Joint Research Centre, European Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Italy
| | - Carole Yauk
- Environmental Health Science and Research Bureau, Health Canada, Canada
| | - Alan Poole
- European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), Belgium.
| |
Collapse
|
20
|
Hartung T, FitzGerald RE, Jennings P, Mirams GR, Peitsch MC, Rostami-Hodjegan A, Shah I, Wilks MF, Sturla SJ. Systems Toxicology: Real World Applications and Opportunities. Chem Res Toxicol 2017; 30:870-882. [PMID: 28362102 PMCID: PMC5396025 DOI: 10.1021/acs.chemrestox.7b00003] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Indexed: 01/14/2023]
Abstract
Systems Toxicology aims to change the basis of how adverse biological effects of xenobiotics are characterized from empirical end points to describing modes of action as adverse outcome pathways and perturbed networks. Toward this aim, Systems Toxicology entails the integration of in vitro and in vivo toxicity data with computational modeling. This evolving approach depends critically on data reliability and relevance, which in turn depends on the quality of experimental models and bioanalysis techniques used to generate toxicological data. Systems Toxicology involves the use of large-scale data streams ("big data"), such as those derived from omics measurements that require computational means for obtaining informative results. Thus, integrative analysis of multiple molecular measurements, particularly acquired by omics strategies, is a key approach in Systems Toxicology. In recent years, there have been significant advances centered on in vitro test systems and bioanalytical strategies, yet a frontier challenge concerns linking observed network perturbations to phenotypes, which will require understanding pathways and networks that give rise to adverse responses. This summary perspective from a 2016 Systems Toxicology meeting, an international conference held in the Alps of Switzerland, describes the limitations and opportunities of selected emerging applications in this rapidly advancing field. Systems Toxicology aims to change the basis of how adverse biological effects of xenobiotics are characterized, from empirical end points to pathways of toxicity. This requires the integration of in vitro and in vivo data with computational modeling. Test systems and bioanalytical technologies have made significant advances, but ensuring data reliability and relevance is an ongoing concern. The major challenge facing the new pathway approach is determining how to link observed network perturbations to phenotypic toxicity.
Collapse
Affiliation(s)
- Thomas Hartung
- Center
for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, United States
- University
of Konstanz, CAAT-Europe, 78457 Konstanz, Germany
| | - Rex E. FitzGerald
- Swiss
Centre for Applied Human Toxicology, University
of Basel, 4055 Basel, Switzerland
| | - Paul Jennings
- Division
of Physiology, Department of Physiology and Medical Physics, Medical University of Innsbruck, 6020 Innsbruck, Austria
| | - Gary R. Mirams
- Centre
for Mathematical Medicine & Biology, School of Mathematical Sciences, University of Nottingham, Nottingham NG7 2RD, U.K.
| | - Manuel C. Peitsch
- Department
of Research and Development, Philip Morris
International, 2000 Neuchâtel, Switzerland
| | - Amin Rostami-Hodjegan
- Centre
for Applied Pharmacokinetic Research, University
of Manchester, Manchester M13 9PL, U.K.
- Simcyp
Limited (a Certara Company), Blades Enterprise
Centre, Sheffield S2 4SU, U.K.
| | - Imran Shah
- National
Center for Computational Toxicology, Research Triangle Park, North Carolina 27711, United States
| | - Martin F. Wilks
- Swiss
Centre for Applied Human Toxicology, University
of Basel, 4055 Basel, Switzerland
| | - Shana J. Sturla
- Department
of Health Sciences and Technology, ETH Zurich, 8092 Zurich, Switzerland
| |
Collapse
|
21
|
Mode-of-action evaluation for the effect of trans fatty acids on low-density lipoprotein cholesterol. Food Chem Toxicol 2016; 98:282-294. [DOI: 10.1016/j.fct.2016.05.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 05/06/2016] [Accepted: 05/26/2016] [Indexed: 01/06/2023]
|
22
|
Perharič L, Fatur T, Drofenik J. European Union's strategy on endocrine disrupting chemicals and the current position of Slovenia. Arh Hig Rada Toksikol 2016; 67:99-105. [PMID: 27331297 DOI: 10.1515/aiht-2016-67-2728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Accepted: 06/01/2016] [Indexed: 11/15/2022] Open
Abstract
In view of the European Union regulations 1107/2009 and 528/2012, which say that basic substances in plant protection and biocidal products marketed in the European Union (EU) should not have an inherent capacity to cause endocrine disruption, an initiative was started to define scientific criteria for the identification of endocrine disruptors (EDs). The objectives of the EU strategy on EDs are to protect human health and the environment, to assure the functioning of the market, and to provide clear and coherent criteria for the identification of EDs that could have broad application in the EU legislation. Policy issues were to be addressed by the Ad-hoc group of Commission Services, EU Agencies and Member States established in 2010, whereas the scientific issues were to be addressed by the Endocrine Disruptors Expert Advisory Group (ED EAG), established in 2011. The ED EAG adopted the 2002 World Health Organization (WHO) definition of endocrine disruptor and agreed that for its identification it is necessary to produce convincing evidence of a biologically plausible causal link between an adverse effect and endocrine disrupting mode of action. In 2014, the European Commission proposed four ED identification criteria options and three regulatory options, which are now being assessed for socio-economic, environmental, and health impact. Slovenia supports the establishing of identification criteria and favours option 4, according to which ED identification should be based on the WHO definition with the addition of potency as an element of hazard characterisation. As for regulatory options, Slovenia favours the risk-based rather than hazard-based regulation.
Collapse
|
23
|
Luijten M, Olthof ED, Hakkert BC, Rorije E, van der Laan JW, Woutersen RA, van Benthem J. An integrative test strategy for cancer hazard identification. Crit Rev Toxicol 2016; 46:615-39. [PMID: 27142259 DOI: 10.3109/10408444.2016.1171294] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Assessment of genotoxic and carcinogenic potential is considered one of the basic requirements when evaluating possible human health risks associated with exposure to chemicals. Test strategies currently in place focus primarily on identifying genotoxic potential due to the strong association between the accumulation of genetic damage and cancer. Using genotoxicity assays to predict carcinogenic potential has the significant drawback that risks from non-genotoxic carcinogens remain largely undetected unless carcinogenicity studies are performed. Furthermore, test systems already developed to reduce animal use are not easily accepted and implemented by either industries or regulators. This manuscript reviews the test methods for cancer hazard identification that have been adopted by the regulatory authorities, and discusses the most promising alternative methods that have been developed to date. Based on these findings, a generally applicable tiered test strategy is proposed that can be considered capable of detecting both genotoxic as well as non-genotoxic carcinogens and will improve understanding of the underlying mode of action. Finally, strengths and weaknesses of this new integrative test strategy for cancer hazard identification are presented.
Collapse
Affiliation(s)
- Mirjam Luijten
- a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | - Evelyn D Olthof
- a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | - Betty C Hakkert
- b Centre for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | - Emiel Rorije
- b Centre for Safety of Substances and Products, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| | | | - Ruud A Woutersen
- d Netherlands Organization for Applied Scientific Research (TNO) , Zeist , the Netherlands
| | - Jan van Benthem
- a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , the Netherlands
| |
Collapse
|
24
|
Carcinogenicity and mode of action evaluation for alpha-hexachlorocyclohexane: Implications for human health risk assessment. Regul Toxicol Pharmacol 2016; 76:152-73. [DOI: 10.1016/j.yrtph.2015.12.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 12/16/2015] [Accepted: 12/17/2015] [Indexed: 01/30/2023]
|
25
|
Borgert CJ, Wise K, Becker RA. Modernizing problem formulation for risk assessment necessitates articulation of mode of action. Regul Toxicol Pharmacol 2015; 72:538-51. [DOI: 10.1016/j.yrtph.2015.04.018] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Revised: 04/17/2015] [Accepted: 04/18/2015] [Indexed: 10/23/2022]
|
26
|
Becker RA, Patlewicz G, Simon TW, Rowlands JC, Budinsky RA. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor. Regul Toxicol Pharmacol 2015; 73:172-90. [PMID: 26145830 DOI: 10.1016/j.yrtph.2015.06.015] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Revised: 06/19/2015] [Accepted: 06/22/2015] [Indexed: 12/29/2022]
Abstract
An Adverse Outcome Pathway (AOP) represents the existing knowledge of a biological pathway leading from initial molecular interactions of a toxicant and progressing through a series of key events (KEs), culminating with an apical adverse outcome (AO) that has to be of regulatory relevance. An AOP based on the mode of action (MOA) of rodent liver tumor promotion by dioxin-like compounds (DLCs) has been developed and the weight of evidence (WoE) of key event relationships (KERs) evaluated using evolved Bradford Hill considerations. Dioxins and DLCs are potent aryl hydrocarbon receptor (AHR) ligands that cause a range of species-specific adverse outcomes. The occurrence of KEs is necessary for inducing downstream biological responses and KEs may occur at the molecular, cellular, tissue and organ levels. The common convention is that an AOP begins with the toxicant interaction with a biological response element; for this AOP, this initial event is binding of a DLC ligand to the AHR. Data from mechanistic studies, lifetime bioassays and approximately thirty initiation-promotion studies have established dioxin and DLCs as rat liver tumor promoters. Such studies clearly show that sustained AHR activation, weeks or months in duration, is necessary to induce rodent liver tumor promotion--hence, sustained AHR activation is deemed the molecular initiating event (MIE). After this MIE, subsequent KEs are 1) changes in cellular growth homeostasis likely associated with expression changes in a number of genes and observed as development of hepatic foci and decreases in apoptosis within foci; 2) extensive liver toxicity observed as the constellation of effects called toxic hepatopathy; 3) cellular proliferation and hyperplasia in several hepatic cell types. This progression of KEs culminates in the AO, the development of hepatocellular adenomas and carcinomas and cholangiolar carcinomas. A rich data set provides both qualitative and quantitative knowledge of the progression of this AOP through KEs and the KERs. Thus, the WoE for this AOP is judged to be strong. Species-specific effects of dioxins and DLCs are well known--humans are less responsive than rodents and rodent species differ in sensitivity between strains. Consequently, application of this AOP to evaluate potential human health risks must take these differences into account.
Collapse
Affiliation(s)
- Richard A Becker
- Regulatory and Technical Affairs Department, American Chemistry Council (ACC), Washington, DC 20002, USA.
| | - Grace Patlewicz
- DuPont Haskell Global Centers for Health and Environmental Sciences, Newark, DE 19711, USA
| | - Ted W Simon
- Ted Simon LLC, 4184 Johnston Road, Winston, GA 30187, USA
| | - J Craig Rowlands
- The Dow Chemical Company, Toxicology & Environmental Research & Consulting, 1803 Building Washington Street, Midland, MI 48674, USA
| | - Robert A Budinsky
- The Dow Chemical Company, Toxicology & Environmental Research & Consulting, 1803 Building Washington Street, Midland, MI 48674, USA
| |
Collapse
|
27
|
Sweeney LM, Kester JE, Kirman CR, Gentry PR, Banton MI, Bus JS, Gargas ML. Risk assessments for chronic exposure of children and prospective parents to ethylbenzene (CAS No. 100-41-4). Crit Rev Toxicol 2015; 45:662-726. [PMID: 25997510 DOI: 10.3109/10408444.2015.1046157] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Potential chronic health risks for children and prospective parents exposed to ethylbenzene were evaluated in response to the Voluntary Children's Chemical Evaluation Program. Ethylbenzene exposure was found to be predominately via inhalation with recent data demonstrating continuing decreases in releases and both outdoor and indoor concentrations over the past several decades. The proportion of ethylbenzene in ambient air that is attributable to the ethylbenzene/styrene chain of commerce appears to be relatively very small, less than 0.1% based on recent relative emission estimates. Toxicity reference values were derived from the available data, with physiologically based pharmacokinetic models and benchmark dose methods used to assess dose-response relationships. An inhalation non-cancer reference concentration or RfC of 0.3 parts per million (ppm) was derived based on ototoxicity. Similarly, an oral non-cancer reference dose or RfD of 0.5 mg/kg body weight/day was derived based on liver effects. For the cancer assessment, emphasis was placed upon mode of action information. Three of four rodent tumor types were determined not to be relevant to human health. A cancer reference value of 0.48 ppm was derived based on mouse lung tumors. The risk characterization for ethylbenzene indicated that even the most highly exposed children and prospective parents are not at risk for non-cancer or cancer effects of ethylbenzene.
Collapse
|
28
|
Futran Fuhrman V, Tal A, Arnon S. Why endocrine disrupting chemicals (EDCs) challenge traditional risk assessment and how to respond. JOURNAL OF HAZARDOUS MATERIALS 2015; 286:589-611. [PMID: 25646754 DOI: 10.1016/j.jhazmat.2014.12.012] [Citation(s) in RCA: 81] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Revised: 12/02/2014] [Accepted: 12/08/2014] [Indexed: 05/11/2023]
Abstract
Endocrine disrupting compounds (EDCs) are a diverse group of "chemicals of emerging concern" which have attracted much interest from the research community since the 1990s. Today there is still no definitive risk assessment tool for EDCs. While some decision making organizations have attempted to design methodology guidelines to evaluate the potential risk from this broadly defined group of constituents, risk assessors still face many uncertainties and unknowns. Until a risk assessment paradigm is designed specifically for EDCs and is vetted by the field, traditional risk assessment tools may be used with caution to evaluate EDCs. In doing so, each issue of contention should be addressed with transparency in order to leverage available information and technology without sacrificing integrity or accuracy. The challenges that EDCs pose to traditional risk assessment are described in this article to assist in this process.
Collapse
Affiliation(s)
- Vivian Futran Fuhrman
- Institute for Dryland, Environmental and Desert Research, The Jacob Blaustein Institutes for Desert Research, Ben-Gurion University of the Negev, Sede Boqer 84990, Israel.
| | - Alon Tal
- Institute for Dryland, Environmental and Desert Research, The Jacob Blaustein Institutes for Desert Research, Ben-Gurion University of the Negev, Sede Boqer 84990, Israel.
| | - Shai Arnon
- Zuckerberg Institute for Water Research, The Jacob Blaustein Institutes for Desert Research, Ben-Gurion University of the Negev, Sede Boqer 84990, Israel.
| |
Collapse
|
29
|
Sakamoto Y, Yoshida M, Tamura K, Takahashi M, Kodama Y, Inoue K. Dose-dependent difference of nuclear receptors involved in murine liver hypertrophy by piperonyl butoxide. J Toxicol Sci 2015; 40:787-96. [DOI: 10.2131/jts.40.787] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- Yohei Sakamoto
- Division of Pathology, National Institute of Health Sciences
- Toxicology Research Department, Pharmaceutical Development Research Laboratories, Teijin Pharma Limited
| | - Midori Yoshida
- Division of Pathology, National Institute of Health Sciences
| | - Kei Tamura
- Division of Pathology, National Institute of Health Sciences
- Toxicology Research Department, Pharmaceutical Development Research Laboratories, Teijin Pharma Limited
| | - Miwa Takahashi
- Division of Pathology, National Institute of Health Sciences
| | - Yukio Kodama
- Division of Toxicology, National Institute of Health Sciences
| | - Kaoru Inoue
- Division of Pathology, National Institute of Health Sciences
| |
Collapse
|
30
|
The history, genotoxicity, and carcinogenicity of carbon-based fuels and their emissions: 1. Principles and background. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH 2014; 762:76-107. [DOI: 10.1016/j.mrrev.2014.07.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Revised: 07/17/2014] [Accepted: 07/20/2014] [Indexed: 12/30/2022]
|
31
|
Simon TW, Simons SS, Preston RJ, Boobis AR, Cohen SM, Doerrer NG, Fenner-Crisp PA, McMullin TS, McQueen CA, Rowlands JC. The use of mode of action information in risk assessment: Quantitative key events/dose-response framework for modeling the dose-response for key events. Crit Rev Toxicol 2014; 44 Suppl 3:17-43. [DOI: 10.3109/10408444.2014.931925] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
32
|
Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS. Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al. Horm Res Paediatr 2014; 80:305-8. [PMID: 24107550 DOI: 10.1159/000355668] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- A C Gore
- Division of Pharmacology and Toxicology, The University of Texas, Austin, Tex., USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
FitzGerald RE, Wilks MF. Bisphenol A--Why an adverse outcome pathway framework needs to be applied. Toxicol Lett 2014; 230:368-74. [PMID: 24831966 DOI: 10.1016/j.toxlet.2014.05.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2014] [Revised: 04/17/2014] [Accepted: 05/03/2014] [Indexed: 11/16/2022]
Abstract
Bisphenol A (BPA) is one of the most widely used and extensively studied chemicals. Numerous studies have reported in vitro effects or animal adverse findings at BPA doses lower than the no observed adverse effect levels (NOAELs) established in regulatory toxicity studies and used for human health risk assessment. Intensive discussions on the adequacy and relevance of test systems have not satisfactorily resolved whether positive or negative animal and/or in vitro findings are more relevant for human health risk assessment purposes. BPA imperfectly mimics endogenous estrogens at membrane-bound estrogen receptors in the fM-nM concentration range, and may have downstream pleiotropic effects such as human seminoma proliferation and mammary gland hyperplasia after in utero exposure which are not detectable in regulatory toxicology studies. We argue that a structured approach like the OECD Adverse Outcome Pathway (AOP) framework is needed to help researchers in designing relevant studies, and risk assessors in evaluating them. The huge amount of experimental data generated for BPA has highlighted data gaps in basic biology and the shortcomings of current approaches to hazard characterization and risk assessment. Establishing AOPs for BPA, and other endocrine active chemicals, will require major scientific as well as training investments by all responsible stakeholders.
Collapse
Affiliation(s)
- R E FitzGerald
- Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland.
| | - M F Wilks
- Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland
| |
Collapse
|
34
|
Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays SM, Hixon JG, Harris MA. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J Appl Toxicol 2014; 34:525-36. [PMID: 23943231 PMCID: PMC4282340 DOI: 10.1002/jat.2907] [Citation(s) in RCA: 109] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Revised: 05/15/2013] [Accepted: 06/02/2013] [Indexed: 01/18/2023]
Abstract
High concentrations of hexavalent chromium [Cr(VI)] in drinking water induce villous cytotoxicity and compensatory crypt hyperplasia in the small intestines of mice (but not rats). Lifetime exposure to such cytotoxic concentrations increases intestinal neoplasms in mice, suggesting that the mode of action for Cr(VI)-induced intestinal tumors involves chronic wounding and compensatory cell proliferation of the intestine. Therefore, we developed a chronic oral reference dose (RfD) designed to be protective of intestinal damage and thus intestinal cancer. A physiologically based pharmacokinetic model for chromium in mice was used to estimate the amount of Cr(VI) entering each intestinal tissue section (duodenum, jejunum and ileum) from the lumen per day (normalized to intestinal tissue weight). These internal dose metrics, together with corresponding incidences for diffuse hyperplasia, were used to derive points of departure using benchmark dose modeling and constrained nonlinear regression. Both modeling techniques resulted in similar points of departure, which were subsequently converted to human equivalent doses using a human physiologically based pharmacokinetic model. Applying appropriate uncertainty factors, an RfD of 0.006 mg kg(-1) day(-1) was derived for diffuse hyperplasia-an effect that precedes tumor formation. This RfD is protective of both noncancer and cancer effects in the small intestine and corresponds to a safe drinking water equivalent level of 210 µg l(-1). This concentration is higher than the current federal maximum contaminant level for total Cr (100 µg l(-1)) and well above levels of Cr(VI) in US drinking water supplies (typically ≤ 5 µg l(-1)).
Collapse
Affiliation(s)
| | | | | | | | - Mina Suh
- ToxStrategies, Inc.Rancho Santa Margarita, CA, 92688, USA
| | - Sean M Hays
- Summit Toxicology, LLPAllenspark, CO, 80510, USA
| | | | | |
Collapse
|
35
|
Pottenger LH, Andrews LS, Bachman AN, Boogaard PJ, Cadet J, Embry MR, Farmer PB, Himmelstein MW, Jarabek AM, Martin EA, Mauthe RJ, Persaud R, Preston RJ, Schoeny R, Skare J, Swenberg JA, Williams GM, Zeiger E, Zhang F, Kim JH. An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride. Crit Rev Toxicol 2014; 44:348-91. [DOI: 10.3109/10408444.2013.873768] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
36
|
Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS. Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al. Horm Behav 2014; 65:190-3. [PMID: 24289987 DOI: 10.1016/j.yhbeh.2013.09.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- A C Gore
- Division of Pharmacology and Toxicology, The University of Texas, Austin, TX 78712, USA.
| | - J Balthazart
- University of Liège, GIGA Neurosciences, B-4000 Liège, Belgium
| | - D Bikle
- VA Medical Center, University of California, San Francisco, San Francisco, CA 94143, USA
| | - D O Carpenter
- Institute for Health and the Environment, University at Albany, State University of New York, Albany, NY 12222, USA
| | - D Crews
- Section of Integrative Biology, The University of Texas, Austin, TX 78712, USA
| | | | | | - R M Dores
- Department of Biological Sciences, University of Denver, Denver, CO 80208, USA
| | - D Grattan
- Department of Anatomy, University of Otago, North Dunedin 9016, New Zealand
| | - P R Hof
- Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA
| | - A N Hollenberg
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
| | - C Lange
- University of Minnesota Masonic Cancer Center, Minneapolis, MN 55455, USA
| | - A V Lee
- University of Pittsburgh Cancer Institute, Magee Women's Research Institute, Pittsburgh, PA 15213, USA
| | - J E Levine
- Wisconsin National Primate Research Center, Madison, WI 53715, USA
| | - R P Millar
- UCT/MRC Receptor Biology Unit, University of Cape Town, Cape Town, South Africa
| | - R J Nelson
- Department of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - M Porta
- Hospital del Mar Institute of Medical Research, School of Medicine, Universitat Autònoma de Barcelona, 080041 Barcelona, Spain
| | - M Poth
- Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
| | - D M Power
- Department of Biosciences, Universidade do Algarve, 8005-139 Faro, Portugal
| | - G S Prins
- Department of Physiology and Biophysics, University of Illinois, Chicago, IL 60612, USA
| | - E C Ridgway
- Department of Medicine, University of Colorado School of Medicine, Denver, CO 80208, USA
| | - E F Rissman
- Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
| | - J A Romijn
- Division of Medicine, Academic Medical Center, University of Amsterdam, 1012 WX Amsterdam, The Netherlands
| | - P E Sawchenko
- Laboratory of Neuronal Structure and Function, The Salk Institute, La Jolla, CA 92037, USA
| | - P D Sly
- Queensland Children's Medical Institute, University of Queensland, Royal Children's Hospital, Brisbane, Queensland 4000, Australia
| | - O Söder
- Karolinska Institutet at Karolinska University Hospital Solna, 171 76 Stockholm, Sweden
| | - H S Taylor
- Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT 06510, USA
| | - M Tena-Sempere
- Department of Cell Biology and Physiology, University of Córdoba, 14071 Córdoba, Spain
| | - H Vaudry
- Institut National de la Santé et de la Recherche Médicale U982, University of Rouen, 76821 Rouen, France
| | - K Wallen
- Department of Psychology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA
| | - Z Wang
- Department of Psychology and Neuroscience, Florida State University, Tallahassee, FL 32306, USA
| | - L Wartofsky
- Department of Medicine, Washington Hospital Center, Washington, DC 20010, USA
| | - C S Watson
- Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA
| |
Collapse
|
37
|
Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS. Reprint of: policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich, et al. Front Neuroendocrinol 2014; 35:2-5. [PMID: 24268499 DOI: 10.1016/j.yfrne.2013.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Accepted: 09/17/2013] [Indexed: 11/24/2022]
Affiliation(s)
- A C Gore
- Pharmacology and Toxicology, The University of Texas at Austin, Austin, TX 78712, United States.
| | - J Balthazart
- University of Liège, GIGA Neurosciences, B-4000 Liège, Belgium
| | - D Bikle
- VA Medical Center and University of California, San Francisco, San Francisco, CA 94143, United States
| | - D O Carpenter
- Institute for Health and the Environment, University at Albany, State University of New York, Albany, NY 12222, United States
| | - D Crews
- Section of Integrative Biology, The University of Texas, Austin, TX 78712, United States
| | - P Czernichow
- Professor Emeritus of Pediatrics, University of Paris, 75006 Paris, France
| | | | - R M Dores
- Department of Biological Sciences, University of Denver, Denver, CO 80208, United States
| | - D Grattan
- Department of Anatomy, University of Otago, North Dunedin 9016, New Zealand
| | - P R Hof
- Icahn School of Medicine at Mt Sinai, New York, NY 10029, United States
| | | | - C Lange
- University of Minnesota Masonic Cancer Center, Minneapolis, MN 55455, United States
| | - A V Lee
- University of Pittsburgh Cancer Institute and Magee Women's Research Institute, Pittsburgh, PA 15213, United States
| | - J E Levine
- Wisconsin National Primate Research Center, Madison, WI 53715, United States
| | - R P Millar
- UCT/MRC Receptor Biology Unit, University of Cape Town, Cape Town, South Africa
| | - R J Nelson
- Department of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States
| | - M Porta
- Hospital del Mar Institute of Medical Research and School of Medicine, Universitat Autònoma de Barcelona, 080041 Barcelona, Spain
| | - M Poth
- Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
| | - D M Power
- Department of Biosciences, Universidade do Algarve, 8005-139 Faro, Portugal
| | - G S Prins
- Department of Physiology and Biophysics, University of Illinois, Chicago, IL 60612, United States
| | - E C Ridgway
- Department of Medicine, University of Colorado School of Medicine, Denver, CO 80208, United States
| | - E F Rissman
- Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA 22908, United States
| | - J A Romijn
- Division of Medicine, Academic Medical Center, University of Amsterdam, 1012 WX Amsterdam, The Netherlands
| | - P E Sawchenko
- Laboratory of Neuronal Structure and Function, The Salk Institute, La Jolla, CA 92037, United States
| | - P D Sly
- Queensland Children's Medical Institute, University of Queensland, Royal Children's Hospital, Brisbane, Queensland 4000, Australia
| | - O Söder
- Karolinska Institutet at Karolinska University Hospital Solna, 171 76 Stockholm, Sweden
| | - H S Taylor
- Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT 06510, United States
| | - M Tena-Sempere
- Department of Cell Biology and Physiology, University of Córdoba, 14071 Córdoba, Spain
| | - H Vaudry
- Institut National de la Santé et de la Recherche Médicale U982, University of Rouen, 76821 Rouen, France
| | - K Wallen
- Department of Psychology and Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, United States
| | - Z Wang
- Department of Psychology and Neuroscience, Florida State University, Tallahassee, FL 32306, United States
| | - L Wartofsky
- Department of Medicine, Washington Hospital Center, Washington, DC 20010, United States
| | - C S Watson
- Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, United States
| |
Collapse
|
38
|
Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS. Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al. Eur J Endocrinol 2013; 169:E1-4. [PMID: 24057478 DOI: 10.1530/eje-13-0763] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A C Gore
- Division of Pharmacology and Toxicology, The University of Texas, Austin, Texas 78712, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Endocrine effects of chemicals: Aspects of hazard identification and human health risk assessment. Toxicol Lett 2013; 223:280-6. [DOI: 10.1016/j.toxlet.2013.03.022] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Revised: 02/27/2013] [Accepted: 03/08/2013] [Indexed: 01/26/2023]
|
40
|
Testai E, Galli CL, Dekant W, Marinovich M, Piersma AH, Sharpe RM. A plea for risk assessment of endocrine disrupting chemicals. Toxicology 2013; 314:51-9. [DOI: 10.1016/j.tox.2013.07.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Accepted: 07/30/2013] [Indexed: 12/20/2022]
|
41
|
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. Toxicon 2013; 76:A1-A2. [DOI: 10.1016/j.toxicon.2013.10.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
42
|
|
43
|
Budinsky RA, Schrenk D, Simon T, Van den Berg M, Reichard JF, Silkworth JB, Aylward LL, Brix A, Gasiewicz T, Kaminski N, Perdew G, Starr TB, Walker NJ, Rowlands JC. Mode of action and dose–response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study. Crit Rev Toxicol 2013; 44:83-119. [DOI: 10.3109/10408444.2013.835787] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
44
|
Corton JC, Cunningham ML, Hummer BT, Lau C, Meek B, Peters JM, Popp JA, Rhomberg L, Seed J, Klaunig JE. Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study. Crit Rev Toxicol 2013; 44:1-49. [PMID: 24180432 DOI: 10.3109/10408444.2013.835784] [Citation(s) in RCA: 161] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Several therapeutic agents and industrial chemicals induce liver tumors in rodents through the activation of the peroxisome proliferator-activated receptor alpha (PPARα). The cellular and molecular events by which PPARα activators induce rodent hepatocarcinogenesis has been extensively studied and elucidated. This review summarizes the weight of evidence relevant to the hypothesized mode of action (MOA) for PPARα activator-induced rodent hepatocarcinogenesis and identifies gaps in our knowledge of this MOA. Chemical-specific and mechanistic data support concordance of temporal and dose-response relationships for the key events associated with many PPARα activators including a phthalate ester plasticizer di(2-ethylhexyl) phthalate (DEHP) and the drug gemfibrozil. While biologically plausible in humans, the hypothesized key events in the rodent MOA, for PPARα activators, are unlikely to induce liver tumors in humans because of toxicodynamic and biological differences in responses. This conclusion is based on minimal or no effects observed on growth pathways, hepatocellular proliferation and liver tumors in humans and/or species (including hamsters, guinea pigs and cynomolgous monkeys) that are more appropriate human surrogates than mice and rats at overlapping dose levels. Overall, the panel concluded that significant quantitative differences in PPARα activator-induced effects related to liver cancer formation exist between rodents and humans. On the basis of these quantitative differences, most of the workgroup felt that the rodent MOA is "not relevant to humans" with the remaining members concluding that the MOA is "unlikely to be relevant to humans". The two groups differed in their level of confidence based on perceived limitations of the quantitative and mechanistic knowledge of the species differences, which for some panel members strongly supports but cannot preclude the absence of effects under unlikely exposure scenarios.
Collapse
|
45
|
Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS. Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrich et al. Endocrinology 2013; 154:3957-60. [PMID: 24048095 PMCID: PMC5398595 DOI: 10.1210/en.2013-1854] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- A C Gore
- PhD, Editor-in-Chief, Endocrinology, Gustavus, Louise Pfeiffer Professor of Pharmacology, Toxicology, The University of Texas at Austin, Austin, Texas 78712.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Meek ME, Boobis A, Cote I, Dellarco V, Fotakis G, Munn S, Seed J, Vickers C. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol 2013; 34:1-18. [PMID: 24166207 PMCID: PMC6701984 DOI: 10.1002/jat.2949] [Citation(s) in RCA: 184] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Accepted: 09/19/2013] [Indexed: 01/25/2023]
Abstract
The World Health Organization/International Programme on Chemical Safety mode of action/human relevance framework has been updated to reflect the experience acquired in its application and extend its utility to emerging areas in toxicity testing and non-testing methods. The underlying principles have not changed, but the framework’s scope has been extended to enable integration of information at different levels of biological organization and reflect evolving experience in a much broader range of potential applications. Mode of action/species concordance analysis can also inform hypothesis-based data generation and research priorities in support of risk assessment. The modified framework is incorporated within a roadmap, with feedback loops encouraging continuous refinement of fit-for-purpose testing strategies and risk assessment. Important in this construct is consideration of dose–response relationships and species concordance analysis in weight of evidence. The modified Bradford Hill considerations have been updated and additionally articulated to reflect increasing experience in application for cases where the toxicological outcome of chemical exposure is known. The modified framework can be used as originally intended, where the toxicological effects of chemical exposure are known, or in hypothesizing effects resulting from chemical exposure, using information on putative key events in established modes of action from appropriate in vitro or in silico systems and other lines of evidence. This modified mode of action framework and accompanying roadmap and case examples are expected to contribute to improving transparency in explicitly addressing weight of evidence considerations in mode of action/species concordance analysis based on both conventional data sources and evolving methods.
Collapse
Affiliation(s)
- M E Meek
- Chemical Risk Assessment, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street, Ottawa, Ontario, Canada, K1N 6N5
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Gore AC, Balthazart J, Bikle D, Carpenter DO, Crews D, Czernichow P, Diamanti-Kandarakis E, Dores RM, Grattan D, Hof PR, Hollenberg AN, Lange C, Lee AV, Levine JE, Millar RP, Nelson RJ, Porta M, Poth M, Power DM, Prins GS, Ridgway EC, Rissman EF, Romijn JA, Sawchenko PE, Sly PD, Söder O, Taylor HS, Tena-Sempere M, Vaudry H, Wallen K, Wang Z, Wartofsky L, Watson CS. Policy decisions on endocrine disruptors should be based on science across disciplines: a response to Dietrichet al. Andrology 2013; 1:802-5. [DOI: 10.1111/j.2047-2927.2013.00151.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- A. C. Gore
- Division of Pharmacology and Toxicology; The University of Texas; Austin TX USA
| | - J. Balthazart
- University of Liège; GIGA Neurosciences; Liège Belgium
| | - D. Bikle
- VA Medical Center and University of California, San Francisco; San Francisco CA USA
| | - D. O. Carpenter
- Institute for Health and the Environment; University at Albany; State University of New York; Albany NY USA
| | - D. Crews
- Section of Integrative Biology; The University of Texas; Austin TX USA
| | | | | | - R. M. Dores
- Department of Biological Sciences; University of Denver; Denver CO USA
| | - D. Grattan
- Department of Anatomy; University of Otago; North Dunedin New Zealand
| | - P. R. Hof
- Icahn School of Medicine at Mt Sinai; New York NY USA
| | - A. N. Hollenberg
- Beth Israel Deaconess Medical Center; Harvard Medical School; Boston MA USA
| | - C. Lange
- University of Minnesota Masonic Cancer Center; Minneapolis MN USA
| | - A. V. Lee
- University of Pittsburgh Cancer Institute and Magee Women's Research Institute; Pittsburgh PA USA
| | - J. E. Levine
- Wisconsin National Primate Research Center; Madison WI USA
| | - R. P. Millar
- UCT/MRC Receptor Biology Unit; University of Cape Town; Cape Town South Africa
| | - R. J. Nelson
- Department of Neuroscience; The Ohio State University Wexner Medical Center; Columbus OH USA
| | - M. Porta
- Hospital del Mar Institute of Medical Research and School of Medicine; Universitat Autònoma de Barcelona; Barcelona Spain
| | - M. Poth
- Uniformed Services University of the Health Sciences; Bethesda MD USA
| | - D. M. Power
- Department of Biosciences; Universidade do Algarve; Faro Portugal
| | - G. S. Prins
- Department of Physiology and Biophysics; University of Illinois; Chicago IL USA
| | - E. C. Ridgway
- Department of Medicine; University of Colorado School of Medicine; Denver CO USA
| | - E. F. Rissman
- Department of Biochemistry and Molecular Genetics; School of Medicine; University of Virginia; Charlottesville VA USA
| | - J. A. Romijn
- Division of Medicine; Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands
| | - P. E. Sawchenko
- Laboratory of Neuronal Structure and Function; The Salk Institute; La Jolla CA USA
| | - P. D. Sly
- Queensland Children's Medical Institute; University of Queensland; Royal Children's Hospital; Brisbane Qld Australia
| | - O. Söder
- Karolinska Institutet at Karolinska University Hospital Solna; Stockholm Sweden
| | - H. S. Taylor
- Department of Obstetrics, Gynecology and Reproductive Sciences; Yale School of Medicine; New Haven CT USA
| | - M. Tena-Sempere
- Department of Cell Biology and Physiology; University of Córdoba; Córdoba Spain
| | - H. Vaudry
- Institut National de la Santé et de la Recherche Médicale U982; University of Rouen; Rouen France
| | - K. Wallen
- Department of Psychology and Yerkes National Primate Research Center; Emory University; Atlanta GA USA
| | - Z. Wang
- Department of Psychology and Neuroscience; Florida State University; Tallahassee FL USA
| | - L. Wartofsky
- Department of Medicine; Washington Hospital Center; Washington DC USA
| | - C. S. Watson
- Department of Biochemistry and Molecular Biology; University of Texas Medical Branch; Galveston TX USA
| |
Collapse
|
48
|
Andersen ME, Preston RJ, Maier A, Willis AM, Patterson J. Dose–response approaches for nuclear receptor-mediated modes of action for liver carcinogenicity: Results of a workshop. Crit Rev Toxicol 2013; 44:50-63. [DOI: 10.3109/10408444.2013.835785] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
49
|
Albertini RJ. Vinyl acetate monomer (VAM) genotoxicity profile: Relevance for carcinogenicity. Crit Rev Toxicol 2013; 43:671-706. [DOI: 10.3109/10408444.2013.827151] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
50
|
Dietrich D, von Aulock S, Marquardt HWJ, Blaauboer BJ, Dekant W, Kehrer J, Hengstler JG, Collier AC, Gori GB, Pelkonen O, Lang F, Nijkamp FP, Stemmer K, Li A, Savolainen K, Hayes AW, Gooderham N, Harvey A. Open letter to the European Commission: scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles. Arch Toxicol 2013; 87:1739-41. [PMID: 23979651 DOI: 10.1007/s00204-013-1117-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Accepted: 08/06/2013] [Indexed: 11/25/2022]
|